Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.77 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.77 |
| ▸ | HPSE | Q9Y251 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.49 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675550 | 0.90 | HDAC6 (0.64) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19058580 | 0.87 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675733 | 0.87 | HDAC6 (0.60) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675286 | 0.87 | HPSE (0.61) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9797021 | 0.85 | HDAC6 (0.65) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL13135790 | 0.84 | HDAC6 (0.63) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675486 | 0.84 | HDAC6 (0.76) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL17985190 | 0.83 | HDAC6 (0.62) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2091511 | 0.82 | HDAC6 (0.65) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1675515 | 0.82 | MAPT (0.65) | HDAC6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | claimed |
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. | 2011-04-14 | — | — | US | claimed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | PTC THERAPEUTICS, INC. | 2016-07-14 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289398-B2 | Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith | PTC THERAPEUTICS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8633019-B2 | Methods for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-7868033-B2 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009151546-A2 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| CN-101198598-A | 2- ((hetero) aryl) -benzoxazole compounds and derivatives thereof, compositions, and methods for stabilizing and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS INC (US) | 2008-06-11 | — | — | CN | disclosed |
| EP-1768968-A1 | 2-((HETERO) ARYL)-BENZOXAZOLE COMPOUNDS AND DERIVATIVES, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | Foldrx Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20050282780-A1 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | FOLDRX PHARMACEUTICALS, LLC | 2005-12-22 | — | — | US | disclosed |
| WO-2005113523-A1 | 2-((HETERO) ARYL)-BENZOXAZOLE COMPOUNDS AND DERIVATIVES, COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | FOLDRX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086833-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | HDAC6 161/4885HDAC3 1363/4885HDAC1 1342/4885 |
| US-20160199357-A1 | METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCIATED THEREWITH | UPF1, DNAJC10, RNGTT | HDAC6 2371/4885HDAC3 4224/4885HDAC1 3787/4885 |
| US-20080269191-A1 | Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, NSUN2, RNMT | HDAC6 836/4885HDAC3 2726/4885HDAC1 2234/4885 |
| US-20140135305-A1 | METHODS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, NSUN2, SNRPB2 | HDAC6 161/4885HDAC3 1363/4885HDAC1 1342/4885 |
| US-20050282780-A1 | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, ALB, TTPA | HDAC6 3180/4885HDAC3 4835/4885HDAC1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.